INTRODUCTION

The incidence of cancer continues to rise worldwide, in high-income and especially in low/middle-income countries.\(^1\) Lymphomas, which are malignancies that arise from the lymphoid tissues,\(^2,3\) account for about 5% of all types of cancer in countries such as the United States.\(^4\) In fact, according to the WHO's Globocan 2020...
The distribution of lymphoma subtype and survival rates vary, but NHL and HL generally account for the vast majority of the cases. For example, in the United Kingdom, the most common subtype between 2004 and 2014 were NHL (85.5%) and HL (14.4%). The estimated 5-year overall survival with NHL was 53.7% and with HL it was 78.9%. Similarly, in Spain, between 2014 and 2018, NHL of B-cell origin and HL represented 80% and 12.4% of all lymphomas, respectively; the overall 2-year survival rate after diagnosis was 92% in HL. In Canada, a study found that NHL and HL accounted for 90% and 6% of all lymphomas, respectively; while in the United States, these two subtypes accounted for 90% and 10% of the lymphomas, respectively.

In Saudi Arabia, between 1975 and 2012, NHL and HL comprised 7.5% and 4% of all cancers, making it the third and eight most common type of cancer, respectively. More recently, NHL and HL represented 6.9% and 3.6% of all new cases of cancer in 2015, ranking it as the fourth and sixth most common cancer types among Saudis, respectively. However, there is limited data focusing on the general trend of lymphoma diagnoses and the long-term survival data from Saudi Arabia. Accordingly, this study was conducted with the objective of presenting a 10-year data from a major tertiary care academic center with relevant demographic and clinical data, trends of different lymphoma pathologies, and mature follow-up survival data.

**METHODS**

This retrospective study included all new cases of lymphoma diagnosed in adults (aged ≥18 years) at King Saud University Medical City (KSUMC), Riyadh, Saudi Arabia, from 2008 to 2018, as identified from the Saudi Cancer Registry. KSUMC is one of the largest governmental tertiary care hospitals in Saudi Arabia. Oncology cases at KSUMC comprises those diagnosed within the hospital or referred from other hospitals.

The study was conducted after the protocol was approved by the Institutional Review Board (IRB) of King Saud University. Patient data confidentiality was ensured during the study and access to, collection, and analysis of the data were only by the investigators. Missing data were handled through calculating the ratio from the number of evaluable patients. The manuscript was prepared following the STROBE reporting guidelines.

**RESULTS**

**Epidemiological data**

A total of 422 new lymphoma cases were diagnosed during the study period. The number of cases/year ranged from 28 (7%) in 2009 to 48 (11%) in 2018. The majority of the patients were aged <60 years (median age: 46 years; range: 18–87 years). In addition, males accounted for 59% of the cases, and most were of Saudi nationality (85%). Patients with advanced-stage disease accounted for about three-quarters (72%) of the evaluable cases.

**Lymphoma stages and subtypes**

In terms of staging, 45 (11%), 67 (16%), 70 (17%), and 226 (55%) cases were of Stages I, II, III, and IV, respectively. In addition, B symptoms were present in 227 of 373 evaluable cases (61%). LDL was elevated in 185 of 322 evaluable cases (57%). Regarding extra-nodal disease, GI

**Data collection**

The primary assessed variables pertained to demographic, clinical characteristics, and long-term survival data. Accordingly, the following data were collected: Age, gender, nationality, date of diagnosis, disease stage, presence of B symptoms, lactate dehydrogenase (LDH) level, biopsy site, histology, bone marrow (BM) involvement, gastrointestinal (GI) tract involvement, central nervous system (CNS) involvement, date of last follow up, and survival status (alive or dead). The first six authors completed the data extraction, which was then verified by the last author.

Lymphoma subtypes under histology were classified according to the WHO classification of lymphoid neoplasms. The lymphoma staging was done following the modified Ann–Arbor staging classification.

**Statistical analysis**

The survival outcomes for the univariate analysis were estimated using the Kaplan–Meier method, and P values were determined using the log-rank test. Multivariate analysis of overall survival (OS) was conducted including the following variables: Age, stage, and LDH level. OS was defined as the time from diagnoses until death from any cause. Multivariable Cox proportional hazard regression models were used to assess the effects of the prognostic variables on OS, hazard ratio (HR), and Wald 95% confidence intervals (CIs). All analyses were performed using two-tailed tests, with the type I error rate fixed at 0.05. Simple frequency statistics were used to summarize the remaining variables. Data were analyzed using R Studio version 1.3.1056 and R for Statistical Computing version 4.0.2.

The survival outcomes for the univariate analysis were estimated using the Kaplan–Meier method, and P values were determined using the log-rank test. Multivariate analysis of overall survival (OS) was conducted including the following variables: Age, stage, and LDH level. OS was defined as the time from diagnoses until death from any cause. Multivariable Cox proportional hazard regression models were used to assess the effects of the prognostic variables on OS, hazard ratio (HR), and Wald 95% confidence intervals (CIs). All analyses were performed using two-tailed tests, with the type I error rate fixed at 0.05. Simple frequency statistics were used to summarize the remaining variables. Data were analyzed using R Studio version 1.3.1056 and R for Statistical Computing version 4.0.2.
Involvement was the most common (136 of 405 evaluable patients; 33.5%), followed by BM (82 of 347; 24%), and central nervous system (19 of 405; 0.05%) involvement.

Nineteen subtypes of lymphoma were identified, and are listed as follows in descending order: diffuse large B-cell lymphoma (DLBCL), 175 (41%); classical Hodgkin’s lymphoma (cHL), 138 (33%); FL, 30 (7%) cases; non-Hodgkin’s lymphoma, unclassifiable, 22 (5%); T-cell lymphoma, 11 (3%); Burkitt lymphoma, 7 (2%); marginal zone lymphoma (MZL), 7 (2%); mantle cell lymphoma (MCL), 6 (1%); cutaneous T-cell lymphoma, 5 (1%); lymphoplasmacytic lymphoma (LPL), 4 (1%); mucosa-associated lymphoid tissue (MALT) lymphoma, 4 (1%); non-Hodgkin’s lymphoma, 3 (0.7%), gray zone lymphoma, 2 (0.5%); plasmablastic lymphoma, 2 (0.5%), T-cell lymphoblastic lymphoma, 2 (0.5%); nodular lymphocyte predominant Hodgkin’s lymphoma (NLPHL), 1 (0.2%), peripheral T-cell lymphoma, 1 (0.2%); and case and small lymphocytic lymphoma, 1 (0.2%) [Table 1].

Survival data
On the last follow up, 333 (79%) patients were alive and 89 (21%) had died. Univariate survival analysis was done using log-rank test and KM curves for the whole group, LDH level, age, DLBCL, and cHL groups were created [Figures 2 and 3]. The median follow-up period was 18 months (range: 0–139 months). The multivariable Cox proportional hazard regression model for age, LDH, and disease stage showed that HR for patients aged ≥60 years is 3.44 (95% CI 2–5.9) adjusted for LDH level and disease stage (P = 0.0000069). In advanced-stage disease, the HR is 4.2 (95% CI 1.5–11.8), adjusted for age and LDH level (P = 0.00637). For the elevated LDH level, the HR is 0.5 (95% CI 0.28–0.97), adjusted for age and disease stage (P = 0.04106).

Table 1: Baseline characteristics of the patients (n=422, unless stated otherwise)

| Variable                  | n (%) |
|---------------------------|-------|
| Age (years)               |       |
| <60                       | 319 (76) |
| ≥60                       | 103 (24) |
| Median (range)            | 46 (18-87) |
| Gender                    |       |
| Male                      | 247 (59) |
| Female                    | 175 (41) |
| Nationality               |       |
| Saudi                     | 358 (85) |
| Non-Saudi                 | 64 (15) |
| Stage (n=408)             |       |
| Advanced                  | 295 (72) |
| Limited                   | 113 (28) |
| B symptoms (n=373)        |       |
| Present                   | 227 (61) |
| Absent                    | 146 (39) |
| Pathologic subtype        |       |
| DLBCL                     | 175 (41) |
| CHL                       | 138 (33) |
| FL                        | 30 (7) |
| NHL, unclassifiable       | 22 (5) |
| Others                    | 57 (14) |
| Status on last follow up  |       |
| Alive                     | 333 (79) |
| Dead                      | 89 (21) |

DLBCL – Diffuse large B-cell lymphoma; CHL – Classical Hodgkin’s lymphoma; FL – Follicular lymphoma; NHL – Non-Hodgkin’s lymphoma
DISCUSSION

Our study is one of the largest single institution data regarding survival and epidemiological trends of lymphomas from Saudi Arabia. It was found that the number of cases each year increased slightly and variably during the study period. Most of them were males of a younger age with advanced-stage disease at presentation. The GI system was found to be the most common site of extranodal involvement in our patient population, which is similar to that reported in the international literature. The younger age at diagnosis may be because of the high proportion of young population in Saudi Arabia or a unique biologic difference, which may warrant further studies. Advanced-stage disease on diagnosis could be because of multiple reasons such as delays in patient seeking medical attention due to lack of knowledge or underestimation of the symptoms, visiting multiple institutions before reaching an accurate diagnosis, and/or the aggressiveness of the biologic lymphoma subtype.

The most common lymphoma subtypes reported were DLBCL, cHL, and FL. Compared with previous studies from Saudi Arabia, our findings showed similar pattern of male predominance, median age, and advanced-disease stage at presentation. Moreover, the current and previously available data showed that the most common subtype was DLBCL. Slight male predominance and NHL being the most common type of lymphoma have been reported in studies from different countries.

In our univariate survival analysis, being aged ≥60 years, having high LDH, and an advanced-stage disease were found to be associated with lower survival. In the multivariate Cox proportional hazard regression models including age, LDH level and stage, patients of aged ≥60 years were more likely to die as compared to younger patients, adjusting for disease stage and LDH level. This is an expected finding and goes well with what is reported in many prognostic scores in lymphoma.

Our study has several limitations, including the weakness inherent in retrospective studies. Relapsed data and treatment received were also not collected, as this was beyond the scope of the study. We also recognize that
survival analyses in some subgroups could be underpowered because of the small number of patients. Despite these limitations, the study has several strengths such as mature survival data being reported with a long-term follow-up. Furthermore, the study had a large population, as the single institution is a major tertiary care hospital.

CONCLUSIONS

This study provides a current benchmark of lymphoma cases in Saudi Arabia. A variable increase in the number of cases was observed during the study period. The study found that the survival trends are comparable with those from Western countries; however, some clinical features and patterns differed such as a higher proportion of cHL cases, more cases presenting with advanced stage and at a younger age. Future studies should focus on defining the etiology of these unique differences.

Ethical considerations

The study was approved by the IRB at the College of Medicine, King Saud University, Riyadh, Saudi Arabia, with approval no.: E-19-4176 on August 28, 2019, and renewed on October 20, 2020, for additional contributors. The requirement of patient consent was waived by the IRB based on the study design. The patient’s data confidentiality was ensured as access to data for collection and analysis was limited to the investigators, who adhered to the principles of the Declaration of Helsinki 2013.

Data availability statement

The datasets generated during and/or analyzed during the current study are not publicly available, but are available from the corresponding author on reasonable request.

Peer review

This article was peer-reviewed by two independent and anonymous reviewers.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018;391:1023-75.
2. Dorland N. Dorland’s Medical Dictionary for Health Consumers. 31st ed. Philadelphia: Saunders; 2007. p. 2175.
3. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375-90.
4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7-30.
5. International Agency for Research on Cancer. Globocan 2020; 2020. Available from: https://gco.iarc.fr/today/data/factsheets/populatio ns/900-world-fact-sheets.pdf. [Last accessed on 2021 Nov 30].
6. Smith A, Crouch S, Lax S, Li J, Painter D, Howell D, et al. Lymphoma incidence, survival and prevalence 2004-2014: Sub-type analyses from the UK’s Haematological Malignancy Research Network. Br J Cancer 2015;112:1575-84.
7. Bastos-Oreiro M, Muntaniño A, Panizo C, Gonzalez-Barca E, de Villambrosia SG, Córdoba R, et al. RELINF: Prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group. Ann Hematol 2020;99:799-808.
8. Ye X, Mahmud S, Skrabek P, Lix L, Johnston JB. Long-term time trends in incidence, survival and mortality of lymphomas by subtype among adults in Manitoba, Canada: A population-based study using cancer registry data. BMJ Open 2017;7:e015106.
9. Rauf MS, Akhtar S, Maghfoor I. Changing trends of adult lymphoma in the Kingdom of Saudi Arabia – Comparison of data sources. Asian Pac J Cancer Prev 2015;16:2069-72.
10. Alrawaji A, Alshahrani Z, Alzahrani W, Alomran F, Almadouj A, Abshchri S, et al. Cancer Incidence Report, Saudi Arabia – 2018. Available from: https://nhic.gov.sa/eServices/Documents/1%20SCR%20final%20%20%20%20%20%20%20%20%20%20.pdf. [Last accessed on 2021 Nov 30].
11. Lister TA, Growther D, Sureliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-6.
12. RStudio. Boston: RStudio Public Benefit, Corp [Online]. Available from: https://rstudio.com/products/rstudio//. [Last accessed on 2021 Apr 10; Last updated on 2021 Feb 22].
13. RStudio. The R Project for Statistical Computing, Vienna: R Foundation; [Online] Available from: https://www.r-project.org/. [Last accessed on 2021 Apr 10; Last updated on 2021 Mar 31].
14. AlShemmari SH, Ameen RM, Sajnani KP. Extranodal lymphoma: A comparative study. Hematolology 2008;13:163-9.
15. Economidouus T, Asprou N, Papageorgiou E, Dervenoulas J, Xanthaki K, et al. Primary extranodal non-Hodgkin’s lymphoma in adults: Clinicopathological and survival characteristics. Leuk Lymphoma 1996;21:131-6.
16. d’Amore F, Christensen BE, Brincker H, Pedersen NT, Thorling K, Hastrup J, et al. Clinicopathological features and prognostic factors in extranodal non-Hodgkin lymphomas. Danish LYFO Study Group. Eur J Cancer 1991;27:1291-8.
17. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: Non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000;92:1240-51.
18. International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993;329:987-94.
19. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-61.
20. Solá-Céjiny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-65.
21. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:358-65.
22. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 1998;339:1506-14.